Holen Sie sich die Stockscreener-App
8.91
1.87%
-0.17
Schlusskurs vom Vortag:
$9.08
Offen:
$8.84
24-Stunden-Volumen:
71,449
Relative Volume:
0.62
Marktkapitalisierung:
$289.82M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-2.52%
1M Leistung:
+15.71%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$8.84
$9.25
1-Wochen-Bereich:
$8.52
$9.78
52-Wochen-Spanne:
$6.565
$13.47
Jade Biosciences Inc Stock (JBIO) Company Profile
Firmenname
Jade Biosciences Inc
Sektor
Branche
Telefon
617-443-2400
Adresse
930 WINTER STREET, WALTHAM
Vergleichen Sie JBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JBIO
Jade Biosciences Inc
|
8.883 | 417.63M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.62 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.68 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.20 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
809.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.45 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-09 | Eingeleitet | BTIG Research | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-05-07 | Eingeleitet | Wedbush | Outperform |
| 2025-05-05 | Eingeleitet | Stifel | Buy |
| 2025-05-02 | Eingeleitet | TD Cowen | Buy |
| 2024-06-18 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-06-18 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-06-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-06-17 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-06-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-06-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-03-25 | Fortgesetzt | Jefferies | Buy |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-12-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-08-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-02-11 | Eingeleitet | BTIG Research | Buy |
| 2021-07-26 | Eingeleitet | Cowen | Outperform |
| 2021-07-26 | Eingeleitet | Evercore ISI | Outperform |
| 2021-07-26 | Eingeleitet | Jefferies | Buy |
| 2021-07-26 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Jade Biosciences Inc Aktie (JBIO) Neueste Nachrichten
How Jade Biosciences Inc. stock reacts to inflationary pressuresMarket Activity Recap & Daily Technical Forecast Reports - newser.com
Multi asset correlation models including Jade Biosciences Inc.Index Update & AI Driven Stock Movement Reports - newser.com
Jade Biosciences Inc. stock daily chart insightsJuly 2025 Review & Consistent Profit Trade Alerts - newser.com
Visualizing Jade Biosciences Inc. stock with heatmaps2025 Valuation Update & Safe Capital Growth Tips - newser.com
Jade Biosciences (NASDAQ:JBIO) Research Coverage Started at BTIG Research - Defense World
Visual trend scoring systems applied to Jade Biosciences Inc.2025 Top Gainers & Daily Volume Surge Signals - newser.com
Q3 Earnings Forecast for Jade Biosciences Issued By Wedbush - MarketBeat
BTIG Research Begins Coverage on Jade Biosciences (NASDAQ:JBIO) - MarketBeat
Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Analyzing drawdowns of Jade Biosciences Inc. with statistical toolsAnalyst Upgrade & High Accuracy Swing Trade Signals - newser.com
Jade Biosciences stock initiated with Buy rating at BTIG on APRIL inhibitor potential - Investing.com Canada
BTIG Initiates Coverage of Jade Biosciences (JBIO) with Buy Recommendation - Nasdaq
BTIG Initiates Jade Biosciences at Buy With $28 Price Target - MarketScreener
Jade Biosciences (NASDAQ:JBIO) Receives Sell (E-) Rating from Weiss Ratings - MarketBeat
Jade Biosciences offers $135 million equity through private placement - MSN
Jade Biosciences discloses JADE-201 for autoimmune diseases - BioWorld MedTech
Jade Biosciences Announces JADE201, a Potentially - GlobeNewswire
Jade Biosciences Secures $135 Million In PIPE Deal - Finimize
Jade Biosciences Unveils JADE201 Antibody to Potentially Treat Autoimmune Diseases - MarketScreener
Jade Biosciences unveils JADE201 antibody targeting BAFF-R By Investing.com - Investing.com Nigeria
Jade Biosciences secures $135 million in private financing By Investing.com - Investing.com Canada
Jade Biosciences Secures $135 Million in Private Placement - TipRanks
Jade Biosciences unveils JADE201 antibody targeting BAFF-R - Investing.com
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases - The Manila Times
Jade Biosciences Announces $135 Million Private Placement - GlobeNewswire
Jade Biosciences Announces $135 Million Private Placement - GlobeNewswire Inc.
Real time alert setup for Jade Biosciences Inc. performanceJuly 2025 Price Swings & Expert Curated Trade Setup Alerts - newser.com
How to integrate Jade Biosciences Inc. into portfolio analysis toolsQuarterly Growth Report & Safe Investment Capital Preservation Plans - newser.com
Jade Biosciences, Inc. announced that it expects to receive $135 million in funding - MarketScreener
Tick level data insight on Jade Biosciences Inc. volatility2025 Fundamental Recap & AI Driven Stock Price Forecasts - newser.com
Is Jade Biosciences Inc. stock vulnerable to regulatory risksJuly 2025 Breakouts & Expert Verified Stock Movement Alerts - newser.com
How strong is Jade Biosciences Inc. stock balance sheetQuarterly Earnings Report & High Conviction Buy Zone Alerts - newser.com
What drives Jade Biosciences Inc stock priceCandlestick Pattern Analysis & Minimize Portfolio Damage with Warnings - earlytimes.in
Finanzdaten der Jade Biosciences Inc-Aktie (JBIO)
Es liegen keine Finanzdaten für Jade Biosciences Inc (JBIO) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):